Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Buy The Dip In Gilead : Why A Decrease In Quarterly Sovaldi Revenue Is Expected

      Headlines

      Tue, 16 Sep 2014

      By Pharma Doc : Introduction: Gilead (NASDAQ: GILD ) is an innovative biotech company that ..... antivirals (HIV). Through key acquisitions, Gilead has expanded its pipeline to include Hepatitis ..... easily the biggest drug launch ever. Gilead 's acquision of Calistoga in 2011 for

    2. If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits

      Headlines

      Tue, 16 Sep 2014

      its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only as well or worse than Gilead 's (NASDAQ: GILD ) Sovaldi or Merck's (NYSE: MRK ) nucleotide it acquired from Idenix (NASDAQ: IDIX ), IDX-21437, then ACH-3422

    3. US STOCKS-Biotechs on track for 3rd straight decline as Gilead drags

      Headlines

      Mon, 15 Sep 2014

      NEW YORK, Sept 15 (Reuters) - Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis...

    4. Gilead licenses Sovaldi to Indian firms

      Headlines

      Mon, 15 Sep 2014

      Gilead Sciences (NASDAQ: GILD ) signs non-exclusive license agreements ..... receive a complete technology transfer of Gilead 's manufacturing process to enable ..... prices and pay a royalty on sales to Gilead that will support product registrations

    5. Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

      Headlines

      Mon, 15 Sep 2014

      NEW DELHI/MUMBAI, Sept 15 (Reuters) - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to...

    6. BRIEF- Gilead Sciences says licensed Hep C drug sovaldi to 7 companies

      Headlines

      Mon, 15 Sep 2014

      * Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy

    7. Celgene Looks Unstoppable

      Headlines

      Mon, 15 Sep 2014

      inflammatory related diseases. The company is a cohort in a quartet of large, powerful bio-pharmas. The others are Gilead (NASDAQ: GILD ), Regeneron (NASDAQ: REGN ) and Biogen Idec (NASDAQ: BIIB ). Management is deep and well-respected. Chairman / CEO

    8. FDA tentatively approves Mylan's HIV combo

      Headlines

      Sat, 13 Sep 2014

      Emergency Plan for AIDS Relief). The branded Emtricitabine/tenofovir (200 mg/300 mg) product is Gilead Sciences ' (NASDAQ: GILD ) Truvada . Nevirapine (200 mg) tablets are sold under the brand name Viramune by Boehringer Ingelheim

    9. RPT- Gilead to raise price for new hepatitis C drug above $84,000

      Headlines

      Sat, 13 Sep 2014

      LOS ANGELES, Sept 13 (Reuters) - The next generation version of Gilead Sciences Inc 's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

    10. Gilead to raise price for new hepatitis C drug above $84,000

      Headlines

      Fri, 12 Sep 2014

      LOS ANGELES, Sept 12 (Reuters) - The next generation version of Gilead Sciences Inc 's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.

    « Prev12345Next »
    Content Partners